127 related articles for article (PubMed ID: 25503724)
41. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
Burrell LM; Burchill L; Dean RG; Griggs K; Patel SK; Velkoska E
Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016
[TBL] [Abstract][Full Text] [Related]
42. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Volpe M
QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
[TBL] [Abstract][Full Text] [Related]
43. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system.
Custódio MR; Koike MK; Neves KR; dos Reis LM; Graciolli FG; Neves CL; Batista DG; Magalhães AO; Hawlitschek P; Oliveira IB; Dominguez WV; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2012 Apr; 27(4):1437-45. PubMed ID: 21825304
[TBL] [Abstract][Full Text] [Related]
44. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats.
Bae S; Yalamarti B; Ke Q; Choudhury S; Yu H; Karumanchi SA; Kroeger P; Thadhani R; Kang PM
Cardiovasc Res; 2011 Sep; 91(4):632-9. PubMed ID: 21565836
[TBL] [Abstract][Full Text] [Related]
45. VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.
Wu-Wong JR; Kawai M; Chen YW; Nakane M
Br J Pharmacol; 2011 Sep; 164(2b):551-60. PubMed ID: 21557735
[TBL] [Abstract][Full Text] [Related]
46. Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Watanabe K; Sukumaran V; Veeraveedu PT; Thandavarayan RA; Gurusamy N; Ma M; Arozal W; Sari FR; Lakshmanan AP; Arumugam S; Soetikno V; Rajavel V; Suzuki K
Inflamm Allergy Drug Targets; 2011 Jun; 10(3):218-25. PubMed ID: 21495969
[TBL] [Abstract][Full Text] [Related]
47. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?
Onuigbo MA
Nephron Clin Pract; 2011; 118(4):c407-19. PubMed ID: 21389735
[TBL] [Abstract][Full Text] [Related]
48. Vitamin D and inflammation.
Guillot X; Semerano L; Saidenberg-Kermanac'h N; Falgarone G; Boissier MC
Joint Bone Spine; 2010 Dec; 77(6):552-7. PubMed ID: 21067953
[TBL] [Abstract][Full Text] [Related]
49. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
[TBL] [Abstract][Full Text] [Related]
50. Vitamin D in chronic kidney disease: new potential for intervention.
Mirković K; van den Born J; Navis G; de Borst MH
Curr Drug Targets; 2011 Jan; 12(1):42-53. PubMed ID: 20795938
[TBL] [Abstract][Full Text] [Related]
51. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
Covic A; Voroneanu L; Goldsmith D
Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
[TBL] [Abstract][Full Text] [Related]
52. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.
Ma TK; Kam KK; Yan BP; Lam YY
Br J Pharmacol; 2010 Jul; 160(6):1273-92. PubMed ID: 20590619
[TBL] [Abstract][Full Text] [Related]
53. Clinical epidemiology of cardiovascular disease in chronic kidney disease.
Foley RN
J Ren Care; 2010 May; 36 Suppl 1():4-8. PubMed ID: 20586894
[TBL] [Abstract][Full Text] [Related]
54. Use of vitamin D in chronic kidney disease patients.
Gal-Moscovici A; Sprague SM
Kidney Int; 2010 Jul; 78(2):146-51. PubMed ID: 20505658
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?
Biggar PH; Liangos O; Fey H; Brandenburg VM; Ketteler M
Pediatr Nephrol; 2011 Jan; 26(1):7-18. PubMed ID: 20422225
[TBL] [Abstract][Full Text] [Related]
56. Role of vitamin D in cardiovascular disease.
Verhave G; Siegert CE
Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
[TBL] [Abstract][Full Text] [Related]
57. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
[TBL] [Abstract][Full Text] [Related]
58. Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.
Wu-Wong JR; Noonan W; Nakane M; Brooks KA; Segreti JA; Polakowski JS; Cox B
Int J Endocrinol; 2010; 2010():625852. PubMed ID: 20169119
[TBL] [Abstract][Full Text] [Related]
59. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
60. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.
Di Angelantonio E; Chowdhury R; Sarwar N; Ray KK; Gobin R; Saleheen D; Thompson A; Gudnason V; Sattar N; Danesh J
Circulation; 2009 Dec; 120(22):2177-87. PubMed ID: 19917883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
